Skip to content

Denali Therapeutics Inc. DNLI Preferred Stock, Shares Outstanding

Preferred Stock, Shares Outstanding at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
BridgeBio Pharma logo
BridgeBio PharmaBBIO
ALN
Alnylam PharmaceuticalsALNY
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX

Other financials

Income statement

See full
Revenue-
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.93B+54.2%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0.0×
Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesOutstanding.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Denali Therapeutics Inc.'s preferred stock, shares outstanding?
Denali Therapeutics Inc. (DNLI) reported preferred stock, shares outstanding of $0 in Q1 2026.